| Biotechnology Industry | Healthcare Sector | Dr. Nardo Zaias CEO | OTC GREY Exchange | - ISIN |
| United States Country | - Employees | - Last Dividend | 19 Mar 2010 Last Split | - IPO Date |
Suvanza Pharma, LLC is a pioneering force in the biotechnology sector, specializing in the development of advanced drug delivery systems specifically for dermatologic applications. Originally established under the name Hamilton PNG, the company underwent a significant rebranding to Suvanza Pharma, LLC in March 2010, marking a new chapter in its commitment to innovation in skin care and treatment. With its foundation laid in 2004 and headquartered in the vibrant area of Miami Beach, Florida, Suvanza Pharma stands at the forefront of research and development aimed at addressing complex dermatologic diseases through cutting-edge technologies.
An innovative technology developed by Suvanza Pharma, RapiDerm is designed to revolutionize the treatment of dermatologic conditions. This proprietary skin drug delivery system facilitates the rapid and effective absorption of medications directly through the skin, offering a promising solution for patients suffering from a variety of skin diseases. By leveraging the unique properties of RapiDerm, Suvanza Pharma aims to improve therapeutic outcomes and enhance the quality of life for individuals dealing with challenging skin conditions.